Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT ID: NCT05298423
Last Updated: 2025-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
611 participants
INTERVENTIONAL
2022-05-03
2026-08-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
NCT05226598
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)
NCT04725188
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
NCT03664024
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy
For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles.
As of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy.
pembrolizumab/vibostolimab
Administered as an intravenous (IV) infusion
durvalumab
Administered as an IV infusion
cisplatin
Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3
pemetrexed
Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only
etoposide
Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;
carboplatin
Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
paclitaxel
Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
thoracic radiotherapy
60 Gray \[Gy\] in 2 Gy fractions for 30 days total administered as an external beam radiation
chemotherapy+radiotherapy+durvalumab
For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles.
durvalumab
Administered as an IV infusion
cisplatin
Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3
pemetrexed
Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only
etoposide
Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;
carboplatin
Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
paclitaxel
Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
thoracic radiotherapy
60 Gray \[Gy\] in 2 Gy fractions for 30 days total administered as an external beam radiation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pembrolizumab/vibostolimab
Administered as an intravenous (IV) infusion
durvalumab
Administered as an IV infusion
cisplatin
Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3
pemetrexed
Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only
etoposide
Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;
carboplatin
Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
paclitaxel
Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
thoracic radiotherapy
60 Gray \[Gy\] in 2 Gy fractions for 30 days total administered as an external beam radiation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8
* Is determined to have unresectable, Stage III NSCLC as documented by a multidisciplinary tumor board or by the treating physician in consultation with a thoracic surgeon
* Has no evidence of metastatic disease, indicating Stage IV NSCLC, in whole-body fluorodeoxyglucose (FDG)-positron emission tomography (PET) or FDG-PET/ computed tomography (CT) and CT or magnetic resonance imaging (MRI) scans of diagnostic quality of chest, abdomen, pelvis and brain
* Has measurable disease as defined by RECIST 1.1, with at least 1 lesion being appropriate for selection as a target lesion, as determined by local site investigator/radiology review
* Has not received prior treatment (chemotherapy, targeted therapy, or radiotherapy) for their Stage III NSCLC
* Has provided tumor tissue sample (tissue biopsy \[core, incisional, or excisional\])
* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 assessed within 7 days prior to the first administration of study intervention
* Has a life expectancy of at least 6 months
Exclusion Criteria
* Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or for breast cancer
* Has received major surgery (with the exception of replacement of vascular access) within 4 weeks before randomization. If the participant had a major operation, the participant must have recovered adequately from the procedure and/or any complications from the operation before starting study intervention
* Is expected to require any other form of antineoplastic therapy, while on study
* Has received colony-stimulating factors (e.g., Granulocyte Colony-Stimulating Factor \[G-CSF\], Granulocyte Macrophage Colony-Stimulating Factor \[GM-CSF\], or recombinant erythropoietin) within 28 days prior to the first dose of study intervention
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication
* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
* Has an active autoimmune disease that has required systemic treatment in past 2 years
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has an active infection requiring systemic therapy
* Has a known history of human immunodeficiency virus (HIV) infection
* Has a known history of Hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV ribonucleic acid \[RNA\] qualitative is detected) infection
* Has had an allogenic tissue/solid organ transplant
Pemetrexed-specific Criteria:
* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days (5 days for long-acting agents \[for example, piroxicam\]) before, during, and for at least 2 days after administration of pemetrexed
* Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Long Beach Healthcare System ( Site 2831)
Long Beach, California, United States
VA West Los Angeles Medical Center ( Site 2808)
Los Angeles, California, United States
Millennium Oncology Research Clinic ( Site 2801)
Hollywood, Florida, United States
Mid Florida Hematology and Oncology Center ( Site 2800)
Orange City, Florida, United States
Moffitt Cancer Center ( Site 2818)
Tampa, Florida, United States
University of Chicago Medical Center ( Site 2828)
Chicago, Illinois, United States
Franciscan St. Francis Health ( Site 2812)
Indianapolis, Indiana, United States
MFSMC-HJWCI ( Site 2804)
Baltimore, Maryland, United States
Boston Medical Center ( Site 2829)
Boston, Massachusetts, United States
University of Massachusetts Chan Medical School ( Site 2815)
Worcester, Massachusetts, United States
University of Missouri Hospital ( Site 2839)
Columbia, Missouri, United States
Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837)
Springfield, Missouri, United States
Rutgers Cancer Institute of New Jersey ( Site 2805)
New Brunswick, New Jersey, United States
Icahn School of Medicine at Mount Sinai ( Site 2821)
New York, New York, United States
White Plains Hospital ( Site 2835)
White Plains, New York, United States
Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 2816)
Portland, Oregon, United States
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 2827)
Lancaster, Pennsylvania, United States
Thomas Jefferson University - Clinical Research Institute ( Site 2813)
Philadelphia, Pennsylvania, United States
Millennium Research & Clinical Development ( Site 2811)
Houston, Texas, United States
Central Texas Veterans health care-Oncology & Hematology ( Site 2819)
Temple, Texas, United States
MultiCare Health System ( Site 2817)
Tacoma, Washington, United States
Clinica Adventista Belgrano ( Site 3601)
Caba., Buenos Aires F.D., Argentina
Instituto Médico Río Cuarto ( Site 3600)
Río Cuarto, Córdoba Province, Argentina
Sanatorio Parque ( Site 3602)
Rosario, Santa Fe Province, Argentina
Canberra Hospital ( Site 0010)
Canberra, Australian Capital Territory, Australia
Icon Cancer Centre Hobart ( Site 0003)
Hobart, Tasmania, Australia
Ballarat Health Services-Medical Oncology ( Site 0002)
Ballarat Central, Victoria, Australia
Frankston Hospital-Oncology and Haematology ( Site 0009)
Frankston, Victoria, Australia
St Vincent's Hospital-Oncology Clinical Trials ( Site 0005)
Melbourne, Victoria, Australia
Hospital Nossa Senhora da Conceição ( Site 0111)
Porto Alegre, Rio Grande do Sul, Brazil
Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0105)
Rio de Janeiro, , Brazil
A. C. Camargo Cancer Center-CAPEC ( Site 0102)
São Paulo, , Brazil
FALP-UIDO ( Site 0205)
Santiago, Region M. de Santiago, Chile
Centro de Oncología de Precisión ( Site 0209)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0200)
Santiago, Region M. de Santiago, Chile
James Lind Centro de Investigacion del Cancer ( Site 0202)
Temuco, Región de la Araucanía, Chile
ONCOCENTRO APYS-ACEREY ( Site 0203)
Viña del Mar, Región de Valparaíso, Chile
Biocenter ( Site 0208)
Concepción, Región del Biobío, Chile
Beijing Cancer hospital-intrathoratic deparmtment II ( Site 0328)
Beijing, Beijing Municipality, China
Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 0309)
Beijing, Beijing Municipality, China
Beijing Peking Union Medical College Hospital-pneumology department ( Site 0300)
Beijing, Beijing Municipality, China
Army Medical Center of People's Liberation Army-Oncology Department ( Site 0321)
Chongqing, Chongqing Municipality, China
Fujian Provincial Cancer Hospital ( Site 0316)
Fuzhou, Fujian, China
Fujian Medical University Union Hospital-1 Bingfanglou ( Site 0330)
Fuzhou Fujian, Fujian, China
The First Affiliated hospital of Xiamen University-oncology ( Site 0317)
Xiamen, Fujian, China
Southern Medical University Nanfang Hospital-Department of Oncology ( Site 0336)
Guangzhou, Guangdong, China
Fourth Hospital of Hebei Medical University ( Site 0331)
Shijiazhuang, Hebei, China
Henan Cancer Hospital ( Site 0333)
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0315)
Wuhan, Hubei, China
Hubei Cancer Hospital ( Site 0311)
Wuhan, Hubei, China
Xiangya Hospital Central South University-Oncology department ( Site 0310)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 0307)
Changsha, Hunan, China
The Second Affiliated Hospital of Soochow University ( Site 0314)
Suzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University ( Site 0305)
Zhenjiang, Jiangsu, China
Jilin Cancer Hospital-oncology department ( Site 0319)
Changchun, Jilin, China
Shandong Provincial Hospital ( Site 0326)
Jinan, Shandong, China
Qingdao Central Hospital-Endocrinology ( Site 0332)
Qingdao, Shandong, China
Shanghai Chest Hospital-Radiotherapy Department ( Site 0306)
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center ( Site 0304)
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital-Radiotherapy department ( Site 0335)
Shanghai, Shanghai Municipality, China
Shanxi Cancer Hospital-Pulmonology ( Site 0322)
Taiyuan, Shanxi, China
West China Hospital of Sichuan University ( Site 0324)
Chengdu, Sichuan, China
Tianjin Cancer Hospital ( Site 0329)
Tianjin, Tianjin Municipality, China
Hangzhou Cancer Hospital-Medical Oncology ( Site 0302)
Hangzhou, Zhejiang, China
The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 0308)
Hangzhou, Zhejiang, China
CIMCA ( Site 0501)
San José, Provincia de San José, Costa Rica
PROCLINICAL Pharma ( Site 0504)
San José, Provincia de San José, Costa Rica
Hospital Metropolitano - Sede Lindora ( Site 0503)
Santa Ana, Provincia de San José, Costa Rica
Masarykuv onkologicky ustav ( Site 3500)
Brno, Brno-mesto, Czechia
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 3502)
Ostrava, Moravskoslezský kraj, Czechia
Instituto de Oncologia ( Site 3003)
Santo Domingo, Nacional, Dominican Republic
Onconet ( Site 3002)
Distrito Nacional, Santo Domingo Province, Dominican Republic
Klinikum Chemnitz-Klinik für Innere Medizin IV ( Site 0607)
Chemnitz, Saxony, Germany
LungenClinic Grosshansdorf-Onkologie ( Site 0602)
Großhansdorf, Schleswig-Holstein, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel-Medizinische Klinik II, Hämatologie und Onkolo ( Site 0609)
Kiel, Schleswig-Holstein, Germany
Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 0603)
Berlin, , Germany
Errikos Dunant Hospital Center-Second Department of Oncology and Clinical Trials Unit ( Site 0703)
Athens, Attica, Greece
Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0706)
Athens, Attica, Greece
Sotiria Thoracic Diseases Hospital of Athens ( Site 0704)
Athens, Attica, Greece
Metropolitan Hospital ( Site 0702)
Athens, Attica, Greece
General Oncology Hospital of Kifissia "Agioi Anargiroi"-2nd Department of Medical Oncology ( Site 0705)
Nea Kifissia, Attica, Greece
University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 0700)
Heraklion, Irakleio, Greece
European Interbalkan Medical Center ( Site 0701)
Thessaloniki, , Greece
MEDI-K ( Site 0807)
Guatemala City, , Guatemala
Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 0802)
Guatemala City, , Guatemala
Centro Regional de Sub Especialidades Médicas SA ( Site 0801)
Quetzaltenango, , Guatemala
Centro Medico Integral De Cancerología (CEMIC) ( Site 0805)
Quetzaltenango, , Guatemala
Rambam Health Care Campus-Oncology ( Site 1001)
Haifa, , Israel
Shaare Zedek Medical Center ( Site 1003)
Jerusalem, , Israel
Rabin Medical Center ( Site 1004)
Petah Tikva, , Israel
Sheba Medical Center-ONCOLOGY ( Site 1000)
Ramat Gan, , Israel
Sourasky Medical Center ( Site 1002)
Tel Aviv, , Israel
Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia medica Toraco-Polmonare ( Site 1107)
Napoli, Campania, Italy
Policlinico Universitario Campus Bio-Medico-Radiation Oncology ( Site 1101)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1100)
Milan, Lombardy, Italy
Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1102)
Monza, Lombardy, Italy
Azienda Ospedaliera Spedali Civili di Brescia ( Site 1105)
Brescia, , Italy
Ospedale San Raffaele. ( Site 1104)
Milan, , Italy
Fondazione IRCCS Policlinico San Matteo ( Site 1103)
Pavia, , Italy
National Hospital Organization Shikoku Cancer Center ( Site 1211)
Matsuyama, Ehime, Japan
Kurume University Hospital ( Site 1212)
Kurume, Fukuoka, Japan
Kobe Minimally Invasive Cancer Center ( Site 1210)
Kobe, Hyōgo, Japan
Kanagawa Cancer Center ( Site 1204)
Yokohama, Kanagawa, Japan
Miyagi Cancer Center ( Site 1200)
Natori-shi, Miyagi, Japan
Sendai Kousei Hospital ( Site 1213)
Sendai, Miyagi, Japan
Niigata Cancer Center Hospital ( Site 1205)
Niigata, Niigata, Japan
Kansai Medical University Hospital ( Site 1207)
Hirakata, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital ( Site 1208)
Takatsuki, Osaka, Japan
Saitama Prefectural Cancer Center ( Site 1201)
Ina-machi, Saitama, Japan
Cancer Institute Hospital of JFCR ( Site 1202)
Koto, Tokyo, Japan
Showa Medical University Hospital ( Site 1203)
Shinagawa, Tokyo, Japan
Osaka International Cancer Institute ( Site 1209)
Osaka, , Japan
University Malaya Medical Centre-Clinical Oncology ( Site 1402)
Lembah Pantai, Kuala Lumpur, Malaysia
Hospital Pulau Pinang ( Site 1400)
George Town, Pulau Pinang, Malaysia
Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1401)
Kuala Lumpur, , Malaysia
Actualidad Basada en la Investigación del Cáncer-Lung Cancer ( Site 1505)
Guadalajara, Jalisco, Mexico
Arké SMO S.A. de C.V. ( Site 1504)
Mexico City, Mexico City, Mexico
Centro Oncologico de Chihuahua-Unidad de Investigacion Clinica ( Site 1507)
Chihuahua City, , Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 1501)
Oaxaca City, , Mexico
THE MEDICAL CITY-Cancer Research Center ( Site 3200)
Pasig, National Capital Region, Philippines
Veterans Memorial Medical Center-Section of Oncology ( Site 3201)
Quezon City, National Capital Region, Philippines
Champalimaud Foundation ( Site 2003)
Lisbon, Lisbon District, Portugal
Hospital CUF Descobertas ( Site 2006)
Lisbon, Lisbon District, Portugal
Unidade Local de Saude de Santo António - Hospital Santo António ( Site 2004)
Porto, , Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2001)
Porto, , Portugal
Centrul Medical Medicover Victoria ( Site 2106)
Bucharest, București, Romania
Amethyst Radiotherapy Center ( Site 2102)
Florești, Cluj, Romania
Centrul de Oncologie "Sfântul Nectarie" ( Site 2100)
Craiova, Dolj, Romania
Radiology Therapeutic Center ( Site 2108)
Otopeni, Ilfov, Romania
Cabinet Medical Oncomed ( Site 2101)
Timișoara, Timiș County, Romania
Centrul Medical Neolife- Baneasa ( Site 2110)
Bucharest, , Romania
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2304)
Port Elizabeth, Eastern Cape, South Africa
Wilgers Oncology Centre ( Site 2301)
Pretoria, Gauteng, South Africa
The Oncology Centre ( Site 2300)
Durban, KwaZulu-Natal, South Africa
Abraham Oncology ( Site 2303)
Richards Bay, KwaZulu-Natal, South Africa
Cape Town Oncology Trials ( Site 2306)
Cape Town, Western Cape, South Africa
The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2401)
Suwon, Kyonggi-do, South Korea
Ajou University Hospital-Hematology-Oncology ( Site 2402)
Suwon, Kyonggi-do, South Korea
Chungbuk National University Hospital-Internal medicine ( Site 2400)
Cheongju-si, North Chungcheong, South Korea
Severance Hospital, Yonsei University Health System-Lung Cancer Center ( Site 2403)
Seoul, , South Korea
Hospital Universitari Vall d'Hebron ( Site 2501)
Barcelona, Catalonia, Spain
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 2503)
Barcelona, Catalonia, Spain
CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2502)
Santiago de Compostela, La Coruna, Spain
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2504)
Pozuelo de Alarcón, Madrid, Comunidad de, Spain
Medipol Mega Universite Hastanesi-oncology ( Site 2611)
Stanbul, Istanbul, Turkey (Türkiye)
Ege University Medicine of Faculty-Chest Diseases Department ( Site 2603)
Bornova, İzmir, Turkey (Türkiye)
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2607)
Adana, , Turkey (Türkiye)
Ankara Gülhane Eitim ve Aratrma Hastanesi-Oncology ( Site 2602)
Ankara, , Turkey (Türkiye)
Hacettepe Universitesi-oncology hospital ( Site 2605)
Ankara, , Turkey (Türkiye)
Memorial Ankara Hastanesi-Medical Oncology ( Site 2609)
Ankara, , Turkey (Türkiye)
Ankara City Hospital-Medical Oncology ( Site 2601)
Ankara, , Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2610)
Istanbul, , Turkey (Türkiye)
I.E.U. Medical Point Hastanesi-Oncology ( Site 2612)
Izmir, , Turkey (Türkiye)
Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 2905)
Kropyvnytskyi, Kirovohrad Oblast, Ukraine
Municipal non-profit enterprise "Lviv Territorial Medical Union "Multidisciplinary Clinical Hospital ( Site 2920)
Lviv, Lviv Oblast, Ukraine
Rivne Regional Clinical Hospital ( Site 2919)
Rivne, Rivne Oblast, Ukraine
Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 2900)
Vinnytsia, Vinnytsia Oblast, Ukraine
Volyn Regional clinical hospital. Regional Medical Oncology Centre. Oncology chemotherapy department ( Site 2918)
Lutsk, Volyn Oblast, Ukraine
Universal Clinic Oberig-Oncology Center ( Site 2916)
Kyiv, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-7684A-006
Identifier Type: OTHER
Identifier Source: secondary_id
KEYVIBE-006
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2021220015
Identifier Type: REGISTRY
Identifier Source: secondary_id
PHRR230831-006071
Identifier Type: REGISTRY
Identifier Source: secondary_id
2022-502752-31-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1285-3656
Identifier Type: REGISTRY
Identifier Source: secondary_id
2021-005135-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
7684A-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.